Skip to Content

Novartis AG ADR NVS Stock Quote

| Rating as of


Market Closed

| Currency in USD

  • Last Close 101.86
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 101.82  –  103.60
  • Year Range 74.24  –  105.61
  • Market Cap 210.6733 Bil
  • Volume / Avg 1.4 Mil /  1.3 Mil
  • Price / Sales 4.11
  • Price / Book 4.06
  • Forward Div Yield 3.55%
  • Trailing Div Yield 3.43%

Morningstar‘s Stock Analysis NVS

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Novartis: Sandoz Spinoff Looks on Track for Early October Following Shareholder Support

Damien Conover Sector Director

Analyst Note

| Damien Conover |

Following the recently announced shareholder support for the Sandoz spin-off, we expect Novartis to divest the unit in early October, likely by Oct. 4. We estimate the Sandoz generic drug business contributes just under 10% of Novartis' fair value estimate. Also, we believe the innovative drug segment provides most of the support for Novartis' wide moat, which largely rests on intangible assets driven by continual innovative drug development.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics NVS

Company Profile NVS

Business Description

Novartis develops and manufactures healthcare products through two business segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Lichtstrasse 35
Basel, 4056, CHE
Industry Drug Manufacturers - General
Employees 101,703

Related Articles NVS

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of NVS’s competitive advantage.

Novartis AG ADR


Johnson & Johnson



−$0.47 (0.46%) −$1.13 (0.72%) −$2.00 (0.13%)
Market Cap
210.67 Bil375.05 Bil6.11 Tril
Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Novartis AG ADR Stock

Yes. NVS has a forward dividend yield of 3.43%. See NVS’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

NVS’s market cap is 210.67 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

NVS’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

NVS’s price/sales is 4.11.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

NVS’s price/forward earnings is 28.29.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

NVS’s price/book is 4.06.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See NVS’s valuation ratios compared to the Market Index.

NVS’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare NVS’s historical performance against its industry peers and the overall market.